Head & neck · 2025
Quad Shot-A Tertiary Hospital Experience With a Palliative Radiotherapy Regimen for Head and Neck Cancer.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nikolaidou Eirini, Bostel Tilman, Mayer Arnulf, Wollschläger Daniel, Schmidberger Heinz, Kaufmann Justus
Аннотация
BACKGROUND: Head and neck cancer patients often present with locally advanced disease. For some patients, palliative treatment schedules focused on symptom control are often preferred. Perhaps the most widely used of these is the so-called Quad Shot (QS) regimen.
METHODS: We evaluated 51 patients with head and neck squamous cell carcinomas treated with QS at University Medical Centre Mainz between 2017 and 2024 for response, survival, and toxicity.
RESULTS: Median overall survival was 5.9 (95% CI: 4.3-10.5) months. Thirty-nine patients could be evaluated for response; out of these, 16 patients had an objective response, and 21 patients had stable disease. Only two cases of toxicity Grade 3 or higher were observed and are most likely attributable to other reasons.
CONCLUSION: QS was well tolerated and showed a meaningful response in most patients. Using real-world data from a highly palliative patient cohort, we discuss several considerations for QS prescription.
METHODS: We evaluated 51 patients with head and neck squamous cell carcinomas treated with QS at University Medical Centre Mainz between 2017 and 2024 for response, survival, and toxicity.
RESULTS: Median overall survival was 5.9 (95% CI: 4.3-10.5) months. Thirty-nine patients could be evaluated for response; out of these, 16 patients had an objective response, and 21 patients had stable disease. Only two cases of toxicity Grade 3 or higher were observed and are most likely attributable to other reasons.
CONCLUSION: QS was well tolerated and showed a meaningful response in most patients. Using real-world data from a highly palliative patient cohort, we discuss several considerations for QS prescription.